Down 4.5% today, more than its diagnostic peers' 3.4%; no story names it yet.
Fell on Nov 5
Down 22% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and diagnostic stocks a median 5%.
CAI's Quality Score fell 4 points on Tue, Nov 10, to 10. Its price fell below its average of the last 200 days and its price is now lower than a year ago.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| The company | Sales up 61% on the year |
| Latest filing | 8-K, Nov 4 |
TodayNo story names it yet.
After its last 4 reports it closed -3.5% on average, higher 2 of 4 times.
CAI is #7 of 18 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| 7 |
Expected to report Thu Feb 25, after the close (in 107 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $275.4M, 27% more than a year ago; a profit of $0.05 a share, from $0.08.
“The increase in total revenue was driven primarily by a 27% growth in molecular profiling services revenue, which was $262.7 million for the three months ended September 30, 2026, compared to $207.6 million for the three months ended September 30, 2025.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Molecular Profiling Services | $263M | $252M | $208M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 4)
| Measure | Figure |
|---|---|
| Total revenue | $1.04B to $1.05B |
“The increase was primarily driven by headcount-related costs, increased research and development investment, and marketing expenditures.”
From its results filing (SEC filing · Nov 4)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | -18.2% | -21.6% | not yet |
| Aug 5, 2026 | +15.5% | +21.6% | +35.3% |
| May 7, 2026 | -15.3% | -18.6% | -23.1% |
Sales grew every year from 2023 to 2025, to $812M. It lost money in each of the three years.
RSI 33.6, MACD below signal, below its 50-day, above its 200-day. Not scored.
One insider bought $990K across 1 filing, and 3 insiders sold $27.2M across 5 filings, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: CAI is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
“The precision oncology industry is highly competitive and subject to rapid change.”
CAI scores 10 today, which Breakaway calls Average. It is #7 of 18 in Services-Medical Laboratories by Quality Score, with 1 of 14 chart checks firing. Down 22% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and diagnostic stocks a median 5%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
CAI scores 10 today, which Breakaway calls Average (6 to 10). That is #7 of 18 in Services-Medical Laboratories by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CAI's 10.
One insider bought $990K across 1 filing, and 3 insiders sold $27.2M across 5 filings, in the last 6 months. The newest is John Russel Denton, Insider, who sold $239K on Sep 22. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.